Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:JMAC NASDAQ:SCLX NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.39-8.1%$2.59$2.00▼$4.00$243.24M1.57248,542 shs198,167 shsJMACMaxpro Capital Acquisition$18.95+0.8%$16.09$7.50▼$19.22$254.46M0.0174,040 shs3,930 shsSCLXScilex$9.48+3.0%$7.55$4.20▼$34.27$80.50M1.66207,272 shs83,135 shsSIGASiga Technologies$3.59+2.6%$4.28$3.42▼$9.62$257.49M0.96590,087 shs627,494 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%-4.78%+5.99%-27.13%+14.90%JMACMaxpro Capital Acquisition-0.84%-3.12%+37.42%+39.34%+194.25%SCLXScilex0.00%+21.38%+8.97%+39.41%+48.13%SIGASiga Technologies0.00%-6.99%-16.71%-17.66%-47.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.39-8.1%$2.59$2.00▼$4.00$243.24M1.57248,542 shs198,167 shsJMACMaxpro Capital Acquisition$18.95+0.8%$16.09$7.50▼$19.22$254.46M0.0174,040 shs3,930 shsSCLXScilex$9.48+3.0%$7.55$4.20▼$34.27$80.50M1.66207,272 shs83,135 shsSIGASiga Technologies$3.59+2.6%$4.28$3.42▼$9.62$257.49M0.96590,087 shs627,494 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%-4.78%+5.99%-27.13%+14.90%JMACMaxpro Capital Acquisition-0.84%-3.12%+37.42%+39.34%+194.25%SCLXScilex0.00%+21.38%+8.97%+39.41%+48.13%SIGASiga Technologies0.00%-6.99%-16.71%-17.66%-47.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.40Hold$7.50213.81% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/ASCLXScilex 1.00SellN/AN/ASIGASiga Technologies 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCLX, SIGA, JMAC, and ACIU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)7/1/2026ACIUAC Immune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/16/2026SCLXScilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/15/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/28/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/11/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/8/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/4/2026ACIUAC Immune BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.004/20/2026ACIUAC Immune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$3.70M65.70N/AN/A$0.54 per share4.43JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/ASCLXScilex$30.25M2.66N/AN/A($24.94) per share-0.38SIGASiga Technologies$94.57M2.72$0.33 per share10.78$2.78 per share1.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$85.03M-$0.82N/A14.06N/A-1,788.02%-125.26%-40.85%8/4/2026 (Estimated)JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AN/ASCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)SIGASiga Technologies$23.28M$0.2713.30N/AN/A21.58%10.60%8.94%8/4/2026 (Estimated)Latest SCLX, SIGA, JMAC, and ACIU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026ACIUAC Immune$0.1213N/AN/AN/A$34.05 millionN/A5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/7/2026Q1 2026SIGASiga TechnologiesN/A-$0.05N/A-$0.05N/A$6.24 million4/30/2026Q1 2026ACIUAC Immune-$0.20-$0.19+$0.01-$0.19$0.33 million$1.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC Immune0.110.871.02JMACMaxpro Capital AcquisitionN/AN/AN/ASCLXScilexN/A0.080.07SIGASiga TechnologiesN/A3.252.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%JMACMaxpro Capital Acquisition73.18%SCLXScilex69.67%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%JMACMaxpro Capital Acquisition19.27%SCLXScilex4.50%SIGASiga Technologies2.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140101.77 million97.09 millionOptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableSCLXScilex808.49 million8.11 millionNo DataSIGASiga Technologies4071.72 million69.77 millionOptionableSCLX, SIGA, JMAC, and ACIU HeadlinesRecent News About These CompaniesSiga Technologies (NASDAQ:SIGA) Stock Price Down 3.5% - What's Next?July 9 at 1:59 AM | marketbeat.comIs SIGA Technologies’ (SIGA) Index Shift and ESOP Shelf Registration Reframing Its Defensive Identity?June 30, 2026 | finance.yahoo.comDiscovering SIGA Technologies And 2 Other Compelling Penny StocksMay 22, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.9% After Q1 Revenue Miss And Sharper Net Loss - What's ChangedMay 15, 2026 | finance.yahoo.comSome Investors May Be Willing To Look Past SIGA Technologies' (NASDAQ:SIGA) Soft EarningsMay 14, 2026 | finance.yahoo.comSIGA (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | fool.comSIGA expects Q2 delivery of approximately $13M of oral TPOXX while targeting an FDA PEP submission in the next 12 monthsMay 8, 2026 | msn.comSIGA Technologies, Inc. Q1 2026 Earnings Call SummaryMay 8, 2026 | finance.yahoo.comSIGA Technologies, Inc. (SIGA) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comSIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business UpdateMay 7, 2026 | globenewswire.comSIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%March 28, 2026 | aaii.comASIGA mpox therapy no longer recommended in EUMarch 27, 2026 | msn.comSiga Technologies Declares Special Dividend of 60 CentsMarch 26, 2026 | marketwatch.comSIGA Declares Special Cash Dividend of $0.60 Per ShareMarch 26, 2026 | globenewswire.comSiga Technologies (NASDAQ:SIGA) Options Surge Hits Nasdaq 100 IndexMarch 19, 2026 | kalkinemedia.comKMpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.March 17, 2026 | barrons.comA Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract ProgressMarch 15, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.3% After Mixed 2025 Results and New Biodefense Contract WinsMarch 15, 2026 | finance.yahoo.comSIGA Technologies Eyes TPOXX Growth As New Contracts Meet Lumpy RevenueMarch 14, 2026 | finance.yahoo.comSIGA Technologies Inc (SIGA) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ...March 11, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, SIGA, JMAC, and ACIU Company DescriptionsAC Immune NASDAQ:ACIU$2.39 -0.21 (-8.08%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$2.49 +0.10 (+4.14%) As of 07/10/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Maxpro Capital Acquisition NASDAQ:JMAC$18.95 +0.15 (+0.80%) As of 07/10/2026Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Scilex NASDAQ:SCLX$9.48 +0.28 (+3.04%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$9.48 +0.00 (+0.05%) As of 07/10/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Siga Technologies NASDAQ:SIGA$3.59 +0.09 (+2.57%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$3.59 0.00 (-0.11%) As of 07/10/2026 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
